Could Coronavirus Variants Boost Pfizer's Vaccine Sales By 50%?

Fifteen billion dollars: That's how much Pfizer (NYSE: PFE) projected last month in its Q4 update that it will make this year from its COVID-19 vaccine, BNT162b2. Sure, the company splits profits equally with its partner, BioNTech (NASDAQ: BNTX), but we're still talking about a lot of money.

The actual amount will almost surely be even higher. Since Pfizer's update, the U.S. government has ordered another 100 million doses of BNT162b2. But could Pfizer's revenue from the vaccine be 50% higher because of another factor -- new "variants of concern" of SARS-CoV-2, the coronavirus that causes COVID-19?

Image source: Getty Images.

Continue reading

Source Fool.com